Work

Pharmaceutical wastewater remediation: occurrence, risk assessment, biological and advanced treatment technologies, and regulatory drivers

Year: 2026
Type: preprint
Abstract: Pharmaceutically active compounds (PhACs) reach surface waters through municipal sewage, hospital effluent, and discharges from drug manufacturing, and conventional treatment removes many of them only partially. In this review, we bring together measured occurrence, risk, and performance data to compare conventional, biological, bioremediation, and advanced physicochemical options. A global survey of 1,052 river sites in 104 countries found at least one active pharmaceutical ingredient (API) above a level considered safe at 25.7% of sites, and treated effluent from a plant serving about 90 bulk-drug manufacturers contained up to 31,000 µg/L ciprofloxacin. Across 87 reported full-scale observations, conventional activated sludge removed a median of 92% of ibuprofen, 62% of sulfamethoxazole and only 11% of carbamazepine, with large seasonal and plant-to-plant variation. For high-strength industrial effluent, anaerobic and aerobic biological trains removed 71–97% of chemical oxygen demand (COD) at pilot and full scale, whereas ozonation alone removed only 10–56% and works better as a pre-treatment. Fungal reactors, high-rate algal ponds, and novel constructed wetlands have removed 40–98% of target PhACs in real wastewater but remain at pilot scale. For trace APIs, ozonation followed by biological post-treatment, and powdered or granular activated carbon both meet the 80% removal benchmark at full scale for about 0.07–0.27 CHF/m3; Fenton, solar, electrochemical, and sonochemical processes are better suited to concentrated, low-volume streams such as manufacturing effluent, hospital effluent, and membrane concentrates. Switzerland has required this “quaternary” treatment at selected plants since 2016; Directive (EU) 2024/3019 extends it to large EU plants by 2045, with pharmaceutical and cosmetics producers paying at least 80% of the cost, and Directive (EU) 2026/805 adds eight pharmaceuticals to the EU priority substances list. No single process removes every API. The most promising routes are hybrid trains that combine biological pre-treatment with oxidation or adsorption, together with treatment of hospital and manufacturing streams at source. Transformation products, polar persistent APIs, mixture toxicity, and selection for antimicrobial resistance remain major knowledge gaps.
Source: ChemRxiv
Language: English
Subfield: Pollution
Open Access status: green
OpenAlex ID: W7236444681
Cites: 48
Cited by:
Related to: 10